rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ENTA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Enanta Pharmaceuticals at Jefferies conference: pipeline grows, costs cut
      12h agoInvesting.comENTAJEF
      Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
      Nov 16Yahoo FinanceENTA
      Enanta Pharmaceuticals Announces CEO Retirement and COO Appointment

      Detailed price information for Enanta Pharmaceutica (ENTA-Q) from The Globe and Mail including charting and trades.

      Oct 29The Globe and MailENTA
      Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

      Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company. Dr. Luly will continue to...

      Oct 28NasdaqENTA
      Enanta begins phase 2b/3 trial for RSV treatment zelicapavir
      Oct 26Investing.comENTA
      Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
      Oct 13Yahoo FinanceENTA
      Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright
      Sep 23Investing.comENTA
      H.C. Wainwright Remains a Buy on Enanta Pharmaceuticals (ENTA)

      Detailed price information for Enanta Pharmaceutica (ENTA-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailENTA
      Enanta at H.C. Wainwright conference: RSV path sharpens
      Sep 16Investing.comENTA
      Enanta Pharmaceuticals to Participate in September Investor Conferences

      WATERTOWN, Mass., September 01, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September:

      Sep 1Yahoo FinanceENTA

      This is the newest page. Registered accounts read further back.